Abstract
Tumor necrosis factor α (TNFα)-blocking agents have been used increasingly in the treatment of severe refractory juvenile idiopathic arthritis (JIA). However, some patients have been forced to discontinue these agents because of the lack of efficacy or adverse events. In these situations, cases of switching from one TNF-blocking agent to another are reported in rheumatoid arthritis, but there are few cases in JIA. This report documents the case of a patient with JIA who improved following a switch from etanercept to infliximab.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
V Gerloni I Pontikaki M Gattinara F Desiati E Lupi A Lurati et al. (2005) ArticleTitleEfficacy of repeated intravenous infusions of an anti-tumor necrosis factor α monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis Arthritis Rheum 52 548–53 Occurrence Handle15693004 Occurrence Handle10.1002/art.20793 Occurrence Handle1:CAS:528:DC%2BD2MXit1GjtLY%3D
DJ Lovell EH Giannini PH Andreas Reiff GD Cawkwell ED Silverman JJ Nocton InstitutionalAuthorNameFor the Pediatric Rheumatology Collaborative Study Group et al. (2000) ArticleTitleEtanercept in children with polyarticular juvenile rheumatoid arthritis N Engl J Med 342 763–9 Occurrence Handle10717011 Occurrence Handle10.1056/NEJM200003163421103 Occurrence Handle1:CAS:528:DC%2BD3cXit1Smu7k%3D
LW Moreland SW Baumgartner MH Schiff EA Tindall RM Fleischmann AL Weaver et al. (1997) ArticleTitleTreatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein N Engl J Med 337 141–7 Occurrence Handle9219699 Occurrence Handle10.1056/NEJM199707173370301 Occurrence Handle1:CAS:528:DyaK2sXlt1Smur0%3D
MJ Elliott RN Maini M Feldmann JR Kalden C Antoni JS Smolen et al. (1994) ArticleTitleRandomised double-blind comparison of chimerical monoclonal antibody to tumor necrosis factor α versus placebo in rheumatoid arthritis Lancet 344 1105–10 Occurrence Handle7934491 Occurrence Handle10.1016/S0140-6736(94)90628-9 Occurrence Handle1:STN:280:ByqD38%2FhslE%3D
Y Yazici D Erkan (2004) ArticleTitleDo etanercept naïve patients respond better to infliximab than RA patients who have failed ETA? Ann Rheum Dis 63 607–8 Occurrence Handle15082503 Occurrence Handle1:STN:280:DC%2BD2c7osFShtw%3D%3D
O Brocq Y Plubel V Breuil C Grisot P Flory A Mousnier et al. (2002) ArticleTitleEtanercept–infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFα Presse Med 31 1836–9 Occurrence Handle12496713 Occurrence Handle1:STN:280:DC%2BD38jjsVCiuw%3D%3D
R van Vollenhoven A Harju S Brannemark L Klareskog (2003) ArticleTitleTreatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumor necrosis factor αblockers can make sense Ann Rheum Dis 62 1195–8 Occurrence Handle14644858 Occurrence Handle10.1136/ard.2003.009589 Occurrence Handle1:CAS:528:DC%2BD2cXit1Wntw%3D%3D
HT Ang S Helfgott (2003) ArticleTitleDo the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 30 IssueID11 2315–8 Occurrence Handle14677170 Occurrence Handle1:CAS:528:DC%2BD2cXhvFags7w%3D
KE Hansen JP Hildebrand MC Genovese JJ Cush S Patel DA Cooley et al. (2004) ArticleTitleThe efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis J Rheumatol 31 1098–102 Occurrence Handle15170921 Occurrence Handle1:CAS:528:DC%2BD2cXlsFWgtrY%3D
EG Avalli M Arreghini C Arnoldi B Panni A Marchesoni S Tosi et al. (2004) ArticleTitleAnti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis Arthritis Rheum 51 301–2 Occurrence Handle10.1002/art.20242
B Andersson Gare A Fasth I Wiklund (1993) ArticleTitleMeasurement of functional status in juvenile chronic arthritis: evaluation of a Swedish version of the childhood health assessment questionnaire Clin Exp Rheumatol 11 569–76 Occurrence Handle8275596 Occurrence Handle1:STN:280:ByuC3c7nsFM%3D
EH Giannini N Ruperto A Ravelli DJ Lovell DT Felson A Martini (1997) ArticleTitlePreliminary definition of improvement in juvenile arthritis Arthritis Rheum 40 1202–9 Occurrence Handle9214419 Occurrence Handle1:STN:280:ByiA2Mjgs1w%3D
JM van den Brande H Braat GR van den Brink HH Versteeg CA Bauer I Hoedemaeker et al. (2003) ArticleTitleInfliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease Gastroenterology 124 1774–85 Occurrence Handle12806611 Occurrence Handle10.1016/S0016-5085(03)00382-2 Occurrence Handle1:CAS:528:DC%2BD3sXlt1yrt7Y%3D
S Takei D Groh B Bernstein B Shaham K Gallagher A Reiff (2001) ArticleTitleSafety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis J Rheumatol 28 1677–80 Occurrence Handle11469478 Occurrence Handle1:CAS:528:DC%2BD3MXlsVyms7Y%3D
EW St Clair CL Wagner AA Fasanmade B Wang T Schaible A Kavanaugh et al. (2004) ArticleTitleThe relationship of serum concentrations to clinical improvement in rheumatoid arthritis: result from ATTRACT: a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 46 1451–9 Occurrence Handle10.1002/art.10302
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Nerome, Y., Imanaka, H., Nonaka, Y. et al. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis. Mod Rheumatol 17, 526–528 (2007). https://doi.org/10.1007/s10165-007-0634-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10165-007-0634-3